BRPI1007972A2 - composições de combinação e métodos para o tratamento de câncer - Google Patents

composições de combinação e métodos para o tratamento de câncer

Info

Publication number: BRPI1007972A2
Authority: BR; Brazil
Prior art keywords: methods; cancer treatment; combination compositions; compositions; combination
Prior art date: 2009-02-12

Application number

BRPI1007972A

Other languages

English (en)

Inventor

Dennis S France

Kenichi Ishil

Paolo Pucci

Thomas C K Chan

Original Assignee

Arqule Inc

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-12

Filing date

2010-02-11

Publication date

2016-09-13

2010-02-11 Application filed by Arqule Inc, Kyowa Hakko Kirin Co Ltd filed Critical Arqule Inc

2016-09-13 Publication of BRPI1007972A2 publication Critical patent/BRPI1007972A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI1007972A 2009-02-12 2010-02-11 composições de combinação e métodos para o tratamento de câncer BRPI1007972A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15213809P	2009-02-12	2009-02-12
US17047109P	2009-04-17	2009-04-17
PCT/US2010/023893 WO2010093789A2 (en)	2009-02-12	2010-02-11	Combinational compositions and methods for treatment of cancer

Publications (1)

Publication Number	Publication Date
BRPI1007972A2 true BRPI1007972A2 (pt)	2016-09-13

Family

ID=42126095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007972A BRPI1007972A2 (pt)	2009-02-12	2010-02-11	composições de combinação e métodos para o tratamento de câncer

Country Status (13)

Country	Link
US (2)	US20100297075A1 (pt)
EP (1)	EP2396003B1 (pt)
JP (1)	JP5687209B2 (pt)
KR (1)	KR101620654B1 (pt)
CN (1)	CN102481299B (pt)
AU (1)	AU2010213696B2 (pt)
BR (1)	BRPI1007972A2 (pt)
CA (1)	CA2752232C (pt)
IL (1)	IL214348A (pt)
MX (1)	MX2011008584A (pt)
TW (1)	TWI460178B (pt)
WO (1)	WO2010093789A2 (pt)
ZA (1)	ZA201105611B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102481299B (zh)	2009-02-12	2015-02-25	艾科尔公司	包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
US8580764B2 (en)	2010-07-01	2013-11-12	Arqule, Inc.	Combinational compositions and methods for treatment of cancer
TW201221126A (en)	2010-09-01	2012-06-01	Arqule Inc	Methods for treatment of non-small cell lung cancer
US8709420B2 (en) *	2010-12-17	2014-04-29	Glaxosmithkline Intellectual Property Limited	Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
TWI525091B (zh)	2010-12-23	2016-03-11	亞闊股份有限公司	吡咯並喹啉基－吡咯啶－２，５－二酮組成物類及製備和使用彼等之方法
JP6253991B2 (ja)	2011-03-02	2017-12-27	ジェロームシェンターク，	肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
US9180099B2 (en)	2011-07-07	2015-11-10	Arqule Inc.	Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2013043715A1 (en) *	2011-09-19	2013-03-28	Genentech, Inc.	Combination treatments comprising c-met antagonists and b-raf antagonists
WO2013085902A1 (en) *	2011-12-05	2013-06-13	The University Of Texas M.D.	Combination therapy methods for treating an inflammatory breast cancer
TWI594986B (zh) *	2011-12-28	2017-08-11	Taiho Pharmaceutical Co Ltd	Antineoplastic agent effect enhancer
EP2841069A4 (en) *	2012-04-23	2015-09-02	Arqule Inc	HIGHLY PYRROLOCHINOLINYL-PYRROL-2,5-DION AND PYRROLOCHINOLINYL-PYRROLIDIN-2,5-DION AND METHOD FOR THE PRODUCTION THEREOF
CN102757435B (zh) *	2012-06-21	2014-05-28	成都苑东药业有限公司	一种反式-3-吲哚基-4-吲哚并二氮杂卓环庚烷基-2,5-吡咯烷-2,5-二酮化合物及其制备方法
KR20160137599A (ko)	2014-03-24	2016-11-30	제넨테크, 인크.	C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
PT3388420T (pt) *	2015-12-07	2022-09-20	Hinova Pharmaceuticals Inc	Compostos de quinolina, método de preparação dos mesmos e uso dos mesmo como fármaco inibidor do transportador de urato
CA3053739C (en)	2017-02-15	2023-02-14	Taiho Pharmaceutical Co., Ltd.	Pharmaceutical composition
JP7074760B2 (ja)	2017-09-08	2022-05-24	大鵬薬品工業株式会社	抗腫瘍剤及び抗腫瘍効果増強剤
CN108546244B (zh) *	2018-07-05	2021-04-23	南昌航空大学	一种3,3’-二吲哚乙烷类化合物的合成方法
US20240058335A1 (en) *	2021-01-08	2024-02-22	Duke University	Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway
EP4601643A1 (en) *	2022-11-18	2025-08-20	Council Of Scientific & Industrial Research	Composition for treating paclitaxel-resistant breast cancer and method for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RS51826B (sr) *	2005-02-09	2012-02-29	Arqule Inc.	Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera
AU2008239594B2 (en)	2007-04-13	2013-10-24	Beth Israel Deaconess Medical Center	Methods for treating cancer resistant to ErbB therapeutics
CA2690799C (en) *	2007-06-22	2015-06-16	Arqule, Inc.	Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CN101918579A (zh)	2007-10-22	2010-12-15	先灵公司	完全人抗-vegf抗体和使用方法
JP2011515478A (ja)	2008-03-25	2011-05-19	シェーリングコーポレイション	結腸直腸がんを処置または予防するための方法
CN102481299B (zh)	2009-02-12	2015-02-25	艾科尔公司	包括与第二抗增殖性试剂结合的(-)-反式-3-(5,6-二氢-4H-吡咯[3,2,1-ij]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮的组合物
US8580764B2 (en) *	2010-07-01	2013-11-12	Arqule, Inc.	Combinational compositions and methods for treatment of cancer
TW201221126A (en) *	2010-09-01	2012-06-01	Arqule Inc	Methods for treatment of non-small cell lung cancer

2010
- 2010-02-11 CN CN201080014223.3A patent/CN102481299B/zh not_active Expired - Fee Related
- 2010-02-11 CA CA2752232A patent/CA2752232C/en not_active Expired - Fee Related
- 2010-02-11 WO PCT/US2010/023893 patent/WO2010093789A2/en not_active Ceased
- 2010-02-11 BR BRPI1007972A patent/BRPI1007972A2/pt not_active IP Right Cessation
- 2010-02-11 EP EP10704696.3A patent/EP2396003B1/en not_active Not-in-force
- 2010-02-11 US US12/704,361 patent/US20100297075A1/en not_active Abandoned
- 2010-02-11 KR KR1020117021339A patent/KR101620654B1/ko not_active Expired - Fee Related
- 2010-02-11 AU AU2010213696A patent/AU2010213696B2/en not_active Ceased
- 2010-02-11 TW TW099104489A patent/TWI460178B/zh not_active IP Right Cessation
- 2010-02-11 JP JP2011550228A patent/JP5687209B2/ja not_active Expired - Fee Related
- 2010-02-11 MX MX2011008584A patent/MX2011008584A/es active IP Right Grant
2011
- 2011-07-28 IL IL214348A patent/IL214348A/en not_active IP Right Cessation
- 2011-07-29 ZA ZA2011/05611A patent/ZA201105611B/en unknown
2015
- 2015-07-24 US US14/807,939 patent/US9642847B2/en active Active

Also Published As

Publication number	Publication date
EP2396003B1 (en)	2013-04-17
JP2012517477A (ja)	2012-08-02
TW201043626A (en)	2010-12-16
CN102481299A (zh)	2012-05-30
AU2010213696A1 (en)	2011-08-18
KR101620654B1 (ko)	2016-05-12
CN102481299B (zh)	2015-02-25
US20150328208A1 (en)	2015-11-19
ZA201105611B (en)	2012-10-31
KR20110118817A (ko)	2011-11-01
HK1164159A1 (en)	2012-09-21
WO2010093789A8 (en)	2011-03-17
EP2396003A2 (en)	2011-12-21
MX2011008584A (es)	2012-01-27
TWI460178B (zh)	2014-11-11
IL214348A (en)	2015-05-31
JP5687209B2 (ja)	2015-03-18
WO2010093789A3 (en)	2010-12-02
IL214348A0 (en)	2011-09-27
US20100297075A1 (en)	2010-11-25
CA2752232A1 (en)	2010-08-19
WO2010093789A2 (en)	2010-08-19
AU2010213696B2 (en)	2015-10-01
US9642847B2 (en)	2017-05-09
CA2752232C (en)	2016-11-22

Publication	Publication Date	Title
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
PT2340042E (pt)	2014-11-27	Métodos e composições para o tratamento de cancro
BRPI1008566A2 (pt)	2017-06-06	métodos e composições para o diagnóstico e tratamento de câncer
BR112012004979A2 (pt)	2015-09-08	composições para o tratamento de semente e métodos
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
BR112012005594A2 (pt)	2015-09-08	tratamento de câncer
BR112012018947A2 (pt)	2017-06-27	composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0908854A2 (pt)	2019-09-24	composições e métodos para o tratamento de tumor de origem hematopoética
PT2434891T (pt)	2020-10-23	Métodos para tratamento de cancro e afeções não neoplásicas
IL218987A0 (en)	2012-06-28	Methods and compositions for treating cancer
BRPI0921321A2 (pt)	2018-10-16	métodos para o tratamento de indwcções e tumores
BRPI1010874A2 (pt)	2017-05-30	composição para o tratamento de câncer de próstata
BRPI1011325A2 (pt)	2016-03-15	composições e métodos para o tratamento de inflamação
PT2512502T (pt)	2018-05-02	Métodos e composições para supressão de tumores
PT2632452T (pt)	2019-01-10	Compostos e composições para o tratamento do cancro
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
PT2367561E (pt)	2015-10-23	Composições e métodos para o tratamento da doença celíaca
BRPI0911112A2 (pt)	2015-10-06	composições e métodos para o tratamento do câncer de mama
BRPI1013618A2 (pt)	2016-04-19	pirimidinas substituídas para o tratamento de câncer
BRPI1007600A2 (pt)	2019-09-24	composições e métodos para tratamento de doenças cardiovasculares
BRPI0922884A2 (pt)	2018-11-06	compostos para tratamento de câncer
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI1007929A2 (pt)	2015-09-01	"métodos e composições para o tratamento de neovascularização".
BRPI1013927A2 (pt)	2016-04-05	métodos e composições para o tratamento de lúpus
IL214349A0 (en)	2011-09-27	Compositions and methods for the treatment of cancer

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-12-04	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2019-03-26	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.